High-dose-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high-risk prostate cancer

Clinical and Translational Oncology

Volumn 10, Issue 7, 2008, Pages 415-421

  Prada, Pedro J ^a   González, Herminio ^a   Fernández, José ^a   Bilbao, Pedro ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Brachytherapy; Conformal; HDR; Prostate cancer; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; BRACHYTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; RADIOTHERAPY; RISK FACTOR;

BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS;

EID: 53749101489     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0223-8     Document Type: Article

References (29)

1. Morgan WR, Bergstralh EJ, Zincke H (1993) Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 41:113
2. Gerber GS, Thisted RA, Chodak GW et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32:385
3. Hanks GE, Diamond JJ, Kual JM et al (1987) Ten-year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 13: 499
4. Pollack A, Zagars GK (1988) External beam radiotherapy dose-response of prostate cancer. Int J Radiat Oncol Biol Phys 15:1299
5. Pollack A, Zagars GK, Smith LG et al (2000) Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate cancer. J. Clin Oncol 18:3904
6. Hanks GE, Hanlon A, Pinover WH et al (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiot Oncol Biol Phys 46 (4):823-832
7. Hanks GE, Martz Kl, Diamond JJ (1988) The effect of dose on local of prostate cancer. Int J Radiat Oncol Biol Phys 15:1299
8. Spiessl B, Bears OH, Hermanek P et al. (eds) (1992) UICC (Union Internationale Contre le Cancer 1989, 1992). Illustrated guide to TNM/pTNM classification of malignant tumors, 3rd ed., 2nd rev. Springer, New York
9. Sobin LH, Wittekind Ch (eds) (1997) TNM classification of malignant tumors (UICC), 5th edn. Wiley, New York
10. Prada PJ, De La Rua A, Hevia M et al (2005) High dose brachytherapy (real time) in patients with intermediate or high risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol 7(9):389-397
11. Roach M, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal Therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974
12. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187
13. SPSS. Versión 11.5
14. Smit WG, Helle PA, Van Putten WL et al (1990) Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18:23
15. Zelefsky MJ, Fuks Z, Hunt M et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol 166:876-881
16. Hanks, GE., Hanlon, AL, Pinover WH et al (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46:823
17. Martinez A, Gonzalez J, Spencer W et al (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169:974-980
18. Galalae RM, Kovács G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81-90
19. Borghede G, Hedelin H, Holmang S et al (1997) Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 44:237-244
20. Mate TP, Gottesman JE, Hatton J et al (1998) High dose-rate afterloading 192 iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 41:525-533
21. Roehl KA, Han M, Ramos CG et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: Long-term results. J Urol 172:910-914
22. Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523
23. Partin AW, Pound CR, Clemens JQ et al (1993) Serum PSA after anatomic radical prostatectomy. The Johns Hopkins Experience after 10 years. Urologic Clinics of North America 20: 713-725
24. Kernen KM, Miles BJ (2000) Prostate cancer treatment outcomes after radical prostatectomy: The Baylor experience (Abstr). Radiother Oncol 55(Suppl. 1):7-8
25. Gerber GS, Thisted RA, Chodak GW et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32:385
26. Prada PJ, Fernández J, Martínez AA et al (2007) Transperineal injection of hyaluronic acid in the anterior peri-rectal fat to decease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Oncol Biol Phys 69(1):99-102
27. Zelefsky MJ, Fuks Z, Wolf T et al (1998) Locally advanced prostate cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy - a dose escalation study. Radiology 209: 169
28. Hanks GE, Lee WR, Hanlon AL et al (1996) Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate specific antigen > or = to 10 ng/ml. Int J Radiat Oncol Biol Phys 35:861.
29. Fernández Luna JL (2007) Apoptosis regulators as targets for cancer therapy. Clinical & Translational Oncology 9:555-562